Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
Public ClinicalTrials.gov record NCT04999969. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumours
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).
Study identification
- NCT ID
- NCT04999969
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 126 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 10, 2021 (Actual)
- Primary completion
- Oct 7, 2024 (Actual)
- Completion
- Nov 30, 2026 (Estimated)
- Last update posted
- Aug 19, 2026
2021 – 2026
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | La Jolla | California | 92037 | — |
| Research Site | Los Angeles | California | 90025 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Ventura | California | 93003 | — |
| Research Site | Atlanta | Georgia | 30318 | — |
| Research Site | Coeur d'Alene | Idaho | 83814 | — |
| Research Site | Boston | Massachusetts | 02114 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Grand Rapids | Michigan | 49503 | — |
| Research Site | Buffalo | New York | 14263 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Portland | Oregon | 97239 | — |
| Research Site | San Antonio | Texas | 78229 | — |
| Research Site | Charlottesville | Virginia | 22908 | — |
| Research Site | Seattle | Washington | 98195 | — |
| Research Site | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04999969, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 19, 2026 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04999969 live on ClinicalTrials.gov.